Bluenote, a San Francisco, CA-based generative AI platform for life sciences companies, raised $10M in financing.
The round was led by Lux Capital, with participation from Elad Gil, Anthropic & Menlo Ventures Anthology Fund, McKesson Ventures, Avichal Garg/Electric Capital, Moxxie Ventures, Carbon Silicon Ventures, and leaders in AI and life sciences – Othman Laraki (CEO Color Health), Fidji Simo (CEO Instacart, Co-founder Metrodora Institute, OpenAI Board), Mike Nohaile (CEO Prellis Biologics, previously Amgen & Novartis Executive), Kristen Fortney (CEO BioAge), Eric Morgen (COO BioAge), Qasar Younis (CEO Applied Intuition), Linus Upson (Verily), and Jeffrey Low (Life sciences investor).
The company intends to use the funds to expand its platform to support additional workflows.
Co-founded by Fatima Sabar and Katsuya Noguchi, Bluenote has developed a generative AI technology platform for life sciences companies to streamline regulatory workflows and bring their innovations to patients asap. Today, the platform’s most widely used applications focus on producing regulatory filings, technical reports, protocols, Standard Operating Procedures (SOPs), validation reports, risk analyses, manufacturing documentation and more. The company has deployed 15+ applications for scientists, engineers, quality, regulatory and manufacturing teams.
FinSMEs
23/12/2024